AR and neoplasm: LSD1 acts as a transcriptional repressor by associating with FOXA1 through the demethylation of H3K4; it also acts as an AR coactivator, and an LSD1 inhibitor suppresses tumor growth synergy with enzalutamide in CRPC cells (22).